Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) major shareholder Ra Capital Management, L.P. acquired 9,906 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was acquired at an average price of $24.46 per share, with a total value of $242,300.76. Following the transaction, the insider owned 6,324,431 shares in the company, valued at approximately $154,695,582.26. The trade was a 0.16% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.81 per share, for a total transaction of $989,149.89.
- On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The stock was purchased at an average price of $24.98 per share, for a total transaction of $37,045.34.
- On Wednesday, May 6th, Ra Capital Management, L.P. bought 68,018 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $24.60 per share, with a total value of $1,673,242.80.
- On Tuesday, May 5th, Ra Capital Management, L.P. bought 97,411 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.63 per share, with a total value of $2,399,232.93.
- On Monday, May 4th, Ra Capital Management, L.P. bought 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $18.00 per share, with a total value of $48,150,000.00.
Hemab Therapeutics Stock Performance
Shares of COAG stock traded down $0.12 on Monday, reaching $25.00. 239,335 shares of the stock were exchanged, compared to its average volume of 376,423. Hemab Therapeutics Holdings, Inc. has a one year low of $23.00 and a one year high of $36.61.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on COAG
Featured Articles
- Five stocks we like better than Hemab Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
